García-Cosmes P, Mortezo A, López-Novoa J M, Macías-Núñez J F
Faculty of Medicine, University of Salamanca, Spain.
Drugs. 1992;44 Suppl 1:99-102. doi: 10.2165/00003495-199200441-00018.
Organ protection is the main goal in the treatment of high blood pressure. Consequently, this protective capacity should be one of the main characteristics of any drug used in the treatment of hypertension. A renal protective agent should protect the kidney from intrinsic renal vasoconstrictors and exogenous agents, and should also protect, or at least delay, the decline in renal function in the presence of renal insufficiency, by mechanisms other than increasing glomerular filtration pressure. Verapamil protects mesangial cells from the reduction in surface area induced by endothelin in vitro. In human subjects, it minimises the renal impairment provoked by the administration of cisplatin, and in mice it protects superficial cortical blood flow from the vasoconstriction elicited by cyclosporin. Finally, verapamil may protect from glomerulosclerosis as a result of its capacity to inhibit mesangial cell replication.
器官保护是高血压治疗的主要目标。因此，这种保护能力应是用于治疗高血压的任何药物的主要特性之一。一种肾脏保护剂应保护肾脏免受内源性肾血管收缩剂和外源性药物的影响，并且还应通过增加肾小球滤过压以外的机制，在存在肾功能不全的情况下保护或至少延缓肾功能的下降。维拉帕米在体外可保护系膜细胞免受内皮素诱导的表面积减少的影响。在人体中，它可将顺铂给药引起的肾损伤降至最低，在小鼠中，它可保护浅表皮质血流免受环孢素引起的血管收缩的影响。最后，维拉帕米可能因其抑制系膜细胞复制的能力而预防肾小球硬化。
